ImmuneSensor Receives Orphan Drug & Rare Disease Designations
20 Nov 2024 //
GLOBENEWSWIRE
ImmuneSensor Initiates Dosing In IMSB301 Phase 1 Trial
08 Oct 2024 //
GLOBENEWSWIRE
ImmuneSensor Granted Patent for Oral cGAS Inhibitors
17 Sep 2024 //
GLOBENEWSWIRE
ImmuneSensor At UBS Virtual Biotechnology Company Symposium
16 Sep 2024 //
GLOBENEWSWIRE
ImmuneSensor Gets Approval For Phase 1 Trial Of IMSB301 In Australia
19 Aug 2024 //
GLOBENEWSWIRE
ImmuneSensor Appoints Thomas Dubensky As CEO, Biopharma Vet
01 May 2024 //
GLOBENEWSWIRE